Phase II Study of Bevacizumab Plus CHOP [cyclophosphamide, doxorubicin, vincristine, prednisolone]-Rituximab in Patients With Untreated Mantle Cell Lymphoma (NHL).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2015
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 18 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
- 18 Apr 2011 Planned End Date changed from 1 Nov 2010 to 1 Jul 2011, according to ClinicalTrials.gov.